The nanocurcumin group, when compared with the placebo, showed significantly increased high-density lipoprotein (HDL) cholesterol, insulin resistance, and decreased fatty liver degree, liver transaminases, waist circumference, hemoglobin A1C (HbA1c), triglycerides, total cholesterol, low-density lipoprotein (LDL), homeostasis model assessment of insulin resistance (HOMA-IR), TNF-α, high-sensitivity C-reactive protein (hs-CRP), and IL-6 [126]. Here, MAP3K14 is linked to Insulin resistance.